Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. HCWB
HCWB logo

HCWB Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy HCW Biologics Inc (HCWB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.090
1 Day change
-0.91%
52 Week Range
7.350
Analysis Updated At
2026/06/19
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

HCW Biologics Inc (HCWB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, there are no significant trading trends, and there is no recent news or major positive catalyst to drive the stock higher in the short term. While analysts have raised the price target and upcoming Phase 1 data could act as a catalyst, the stock's current weak technicals and lack of immediate signals make it better suited for monitoring rather than immediate investment.

Technical Analysis

The technical indicators for HCWB are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 26.559, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 1.078 and resistance at 1.586.

Positive Catalysts

  • Analyst Maxim raised the price target to $5 from $2 and maintained a Buy rating. Upcoming Phase 1 data for HCW9302 in alopecia areata, expected by the end of Q2, could act as a potential catalyst.

Neutral/Negative Catalysts

  • Bearish technical indicators, lack of significant trading trends from hedge funds or insiders, and no recent news to drive momentum.

Financial Performance

No financial data available for analysis.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Maxim has raised the price target to $5 from $2 and maintained a Buy rating. The firm highlights strategic improvements and the potential catalyst of Phase 1 data for HCW9302.

Wall Street analysts forecast HCWB stock price to rise
1 Analyst Rating
Wall Street analysts forecast HCWB stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
sliders
Low
8
Averages
8
High
8
Current: 1.100
sliders
Low
8
Averages
8
High
8
Maxim
Maxim
NULL
to
Buy
upgrade
$2 -> $5
AI Analysis
2026-05-29
Reason
Maxim
Maxim
Price Target
$2 -> $5
AI Analysis
2026-05-29
upgrade
NULL
to
Buy
Reason
Maxim raised the firm's price target on HCW Biologics to $5 from $2 and keeps a Buy rating on the shares. The company has taken several steps to improve its positioning strategically, including reclaiming rights to HCW9206 and advancing its lead asset HCW9302 towards initial Phase 1 data in the next few months, the analyst tells investors in a research note. The most significant upcoming event and potential catalyst for the shares is preliminary data from the Phase 1 study of HCW9302 in alopecia areata, which is expected by the end of Q2, the firm added.

People Also Watch